Navigation Links
Taiho Pharmaceutical presenta una solicitud para fabricar y comercializar el nuevo agente antitumoral TAS-102
Date:2/26/2013

tralia. La reclutación de pacientes comenzó en junio de 2012. Los sujetos son pacientes con cáncer colorrectal no reseccionable, avanzado y recurrente que rechaza las quimioterapias estándares (fluoropirimidina, irinotecan, oxaliplatin, bevacizumab, y anticuerpo monoclonal EGFR en casos de tumor de tipo no mutado KRAS). El ensayo comparará a los pacientes aleatoriamente asignados para recibir TAS-102 o placebo para investigar la eficacia y seguridad de TAS-102. La medida de evaluación principal es la supervivencia general. Los principales investigadores son el doctor Atsushi Otsu , director del Clinical Development Center del National Cancer Center Hospital East (Japón), el doctor Robert J. Mayer del Dana Farber Cancer Institute (USA), y el doctor Eric Van Cutsem del University Hospital Gasthuisberg (Bélgica).

Acerca de Taiho Pharmaceutical Co., Ltd.
Taiho Pharmaceutical, una filial de Otsuka Holdings Co., Ltd. (http://www.otsuka.com/en/), es una compañía farmacéutica de I+D centrada en los tres campos de oncología, alergias e inmunología, y urología. Su filosofía corporativa es una promesa: "Nos esforzamos por mejorar la salud humana y contribuir al enriquecimiento de la sociedad." En particular, en el campo de la oncología, Taiho Pharmaceutical es conocida como una compañía líder en Japón y en todo el mundo por el desarrollo de medicinas basadas en la evidencia para el tratamiento del cáncer. Además, en otras áreas distintas a la oncología, la compañía crea productos de calidad que tratan las enfermedades médicas de forma efectiva y pueden ayudar a mejorar la calidad de vida de las personas. Poniendo siempre al cliente en primer lugar, Taiho Pharmaceutical también pretende ofrecer productos médicos de
'/>"/>

SOURCE Taiho Pharmaceutical Co., Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Taiho Pharmaceutical stellt Zulassungsantrag zur Herstellung und Vermarktung des neuartigen Antitumormittels TAS-102
2. Taiho Pharmaceutical Submits Application for Approval to Manufacture and Market Novel Antitumor Agent TAS-102
3. Taiho Pharmaceutical présente une demande dhomologation pour la fabrication et la commercialisation du nouvel agent antitumoral TAS-102
4. Taiho Pharmaceutical Announces Start of Global Phase III Clinical Trial in Metastatic Colorectal Cancer with Novel Antitumor Agent TAS-102
5. Jazz Pharmaceuticals Reports Full Year And Fourth Quarter 2012 Financial Results
6. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Cowen & Company 33rd Annual Health Care Conference In Boston On March 5, 2013
7. Global Pharmaceutical Industry Trends: Procurement Budgets Stay the Same, Marketing Budgets to Experience Slight Decrease
8. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2012 Financial Results Conference Call on Tuesday, March 19, 2013
9. Savara Pharmaceuticals Announces Formation of Clinical Advisory Board
10. Isis Pharmaceuticals Initiates Phase 2 Study Of ISIS-CRP Rx In Patients With Atrial Fibrillation
11. UBM Launches PharmaEvolution.com, an Online Peer-to-Peer Network for Pharmaceutical Industry Professionals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014 InVivo Therapeutics ... MA is revolutionizing spinal cord injury (SCI) ... been shown to outperform in tissue regrowth in the ... scaffold.  Made from an FDA approved polymer, the scaffold ... it harmless to the human body. NVIV has recently ...
(Date:10/22/2014)... 22, 2014 WHEN: Wednesday, October 29, 2014 ... available at: http://bit.ly/1yStiU9 SPEAKERS: Visionary ... Visionary Innovation Research Group Senior Research Analyst ... materials, nanobots and flexible electronics are among ... our lives in the coming decades. These ...
(Date:10/22/2014)... -- Provectus Biopharmaceuticals, Inc. (NYSEMKT: PVCT) specializes in developing ... for cancer, is designed for injection into solid tumors ... focus is on melanoma, breast cancer and cancers of ... PV-10 as a therapy for metastatic melanoma, and of ... psoriasis. This summer, the Company signed ...
Breaking Medicine Technology:InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 2InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 3Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2
... 8 , - Glivec(R) (imatinib) ... KIT (CD117)-Positive Gastrointestinal Stromal Tumours,(GIST), who are at Significant Risk ... - Use of Glivec(R) After Surgery Significantly Reduces Risk ... After Surgery, 50% of patients Will Experience Their,Cancer Returning Within ...
... guidance regarding strategic transaction processSAN DIEGO, May 7 ... ANX ) today announced results from its bioequivalence ... determined to have comparable overall safety as Taxotere(R), ... groups in severe toxicities. However, pharmacokinetic equivalence, ...
Cached Medicine Technology:Glivec(R) is the First Adjuvant Treatment Approved in the UK to Delay Return of Gastrointestinal Cancer After Surgery 2Glivec(R) is the First Adjuvant Treatment Approved in the UK to Delay Return of Gastrointestinal Cancer After Surgery 3Glivec(R) is the First Adjuvant Treatment Approved in the UK to Delay Return of Gastrointestinal Cancer After Surgery 4Glivec(R) is the First Adjuvant Treatment Approved in the UK to Delay Return of Gastrointestinal Cancer After Surgery 5Glivec(R) is the First Adjuvant Treatment Approved in the UK to Delay Return of Gastrointestinal Cancer After Surgery 6ADVENTRX Announces Results From ANX-514 Bioequivalence Study 2ADVENTRX Announces Results From ANX-514 Bioequivalence Study 3ADVENTRX Announces Results From ANX-514 Bioequivalence Study 4ADVENTRX Announces Results From ANX-514 Bioequivalence Study 5
(Date:10/25/2014)... Interrupting blood supply to an arm or a leg before ... surgery, according to a new study. "During heart ... heart to be able to operate on it. After some ... to produce energy because it doesn,t get oxygen. When we ... as an arm or a leg, the body prepares for ...
(Date:10/25/2014)... News) -- Not getting the right amount of sleep ... study suggests. Those who sleep less or more ... may be more prone to developing the chronic condition, ... study authors concluded that duration and quality of sleep ... inflammatory bowel diseases. "Both short and long durations ...
(Date:10/25/2014)... large influx of international aid is needed, and soon, ... of deaths from the widening Ebola crisis, a team ... specially designed mathematical model, the researchers looked at the ... populated county of hard-hit Liberia -- Montserrado County, home ... said that if international aid isn,t delivered to Liberia ...
(Date:10/25/2014)... HealthDay Reporter FRIDAY, Oct. ... developed that spot increased risks for certain cancers, one might ... screened. But a new study suggests that, at least ... found out their genes doubled their risk of colon cancer ... get screened. "It didn,t make any difference, not at ...
(Date:10/22/2014)... Pennsylvania (PRWEB) October 22, 2014 At ... and uncertainty among parents and athletes at all levels, ... working to change the current discussion where two powerful ... are evidence-based therapies that result in full recoveries every ... to one based in fact and research, UPMC and ...
Breaking Medicine News(10 mins):Health News:Brief Interruption of Blood Supply to Limb Might Aid Heart Surgery: Study 2Health News:Sleep Duration Linked to Ulcerative Colitis Risk in Study 2Health News:Experts Predict 'Catastrophic' Ebola Epidemic in West Africa if Aid Delayed 2Health News:Knowing Genetic Risk for Cancer May Not Change Behavior 2Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 2Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 3Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 4
... S. Department of Health and Human Services (HHS) and ... launch National Infant Immunization Week (NIIW) with events// April ... are expected to participate in NIIW by sponsoring activities ... ,CDC and HHS will collaborate with state ...
... Brodie Campbell are still in shock and grief over the ... have reportedly brought in grief counselors to help students deal ... student at his school- Dr. Charles Best Secondary School in ... has now confirmed the reason of death as bacterial meningitis. ...
... losing its forests to over-exploitation, will get help in ... which signed up the// country as a member this ... Analysis (IIASA), Austria - a non-governmental research organization that ... the context of global change - has said it ...
... Institute of Medical Sciences (AIIMS) has developed artificial testis, ... genitals.// ,Doctors at the premier referral hospital ... such problems, achieving 100 percent success. ,"We ... patients with not a single case of rejection. From ...
... scam burst into the open in Paris, Dr. Brian ... three months by the// Californian state authorities. ... Area Laboratory Co-Operative that allegedly provided steroids to top ... five years' probation and ordered to undergo a psychiatric ...
... too serious a matter to be left in the hands of ... the care of labour department officials. At least such// seems to ... that agencies like the Occupational Safety and Health Administration ... than with the safety of the workers themselves. ...
Cached Medicine News:Health News:National Infant Immunization Week Urges Parents to Vaccinate On Time 2Health News:India to Protect Its Forests With the Aid of Austrian NGO 2Health News:Artificial Testis Developed by AIIMS a Boon to Suffering Patients 2Health News:US Psychiatrist Suspended from Practicing Medicine for Involvement in Doping Scam 2Health News:US Psychiatrist Suspended from Practicing Medicine for Involvement in Doping Scam 3Health News:Overseeing Agency Indifferent to Workplace Safety in US 2
View Mex-3 is designed for out-patient surgery, hospital rounds and house calls....
Headlight module is mounted on UltraLite Plus headband or sweatband....
It is a magnifying headlight perfect for all applications and procedures where clear magnification and a natural white light increase accuracy and productivity....
It is a magnifying headlight perfect for all applications and procedures where clear magnification and a natural white light increase accuracy and productivity....
Medicine Products: